{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:51:02Z","timestamp":1791406262363,"version":"4.3.3"},"reference-count":73,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"\n PURPOSE<\/jats:title>\n \n TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with various solid tumors with\n FGFR1<\/jats:italic>\n or\n FGFR2<\/jats:italic>\n alterations treated with sunitinib are reported.\n <\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n \n Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no remaining standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration (SD16+). Low accruing histology-specific cohorts with\n FGFR1<\/jats:italic>\n or\n FGFR2<\/jats:italic>\n alterations treated with sunitinib were collapsed into two histology-pooled cohorts for this analysis. The hypothesized null DC rate of 15% was evaluated by a 1-sided exact binomial test (alpha .10; 82% power) per cohort. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of SD, and safety.\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n \n Sixty-four patients with 20 different cancer types with\n FGFR1<\/jats:italic>\n (N = 36) or\n FGFR2<\/jats:italic>\n (N = 28) alterations were enrolled from April 2016 to June 2024 and collapsed into two histology-pooled cohorts (\n FGFR1<\/jats:italic>\n and\n FGFR2<\/jats:italic>\n ) for analysis. Eight patients (all in the\n FGFR1<\/jats:italic>\n cohort) were not evaluable for efficacy. DC rates for the\n FGFR1<\/jats:italic>\n and\n FGFR2<\/jats:italic>\n cohorts were 21% (one-sided 90% CI, 12 to 100) and 39% (one-sided 90% CI, 27 to 100), respectively. The null hypothesis was not rejected for the\n FGFR1<\/jats:italic>\n cohort (\n P<\/jats:italic>\n = .24) but was rejected for the\n FGFR2<\/jats:italic>\n cohort (\n P<\/jats:italic>\n = .0015). Twenty patients had at least one treatment-related grade 3-5 adverse event (AE) or serious AE.\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION<\/jats:title>\n \n Sunitinib met the prespecified criteria to declare a signal of activity in patients with various solid tumors and\n FGFR2<\/jats:italic>\n alterations but not\n FGFR1<\/jats:italic>\n alterations.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/po-26-00454","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:59:12Z","timestamp":1791403152000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Sunitinib in Patients With Various Solid Tumors With\n FGFR1<\/i>\n \/\n 2<\/i>\n Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study"],"prefix":"10.1200","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02693535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3519-0409","authenticated-orcid":true,"given":"Gordan","family":"Srkalovic","sequence":"first","affiliation":[{"name":"University Michigan Health-Sparrow Herbert-Herman Cancer Center, Lansing, MI"},{"name":"Michigan Cancer Research Consortium, Ypsilanti, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-7743","authenticated-orcid":true,"given":"Kathryn F.","family":"Mileham","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamidele","family":"Adesunloye","sequence":"additional","affiliation":[{"name":"City of Hope Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[{"name":"City of Hope Chicago, Zion, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Colocci","sequence":"additional","affiliation":[{"name":"Sutter Cancer Research Consortium, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dwight","family":"Chen","sequence":"additional","affiliation":[{"name":"Sutter Cancer Research Consortium, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":true,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-3570","authenticated-orcid":true,"given":"Alissa S.","family":"Marr","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-4725","authenticated-orcid":true,"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-0048","authenticated-orcid":true,"given":"Steven","family":"Powell","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-025X","authenticated-orcid":true,"given":"Jens","family":"Rueter","sequence":"additional","affiliation":[{"name":"Jackson Laboratory-Maine Cancer Genomics Initiative, Bar Harbor, ME"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Benyounes","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8871-9836","authenticated-orcid":true,"given":"Corbin","family":"Pontious","sequence":"additional","affiliation":[{"name":"Kettering Health, Kettering, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-6557","authenticated-orcid":true,"given":"Mark A.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, Sandy, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Lewis Cancer & Research Pavilion at St Joseph's Candler, Savannah, GA"},{"name":"South Carolina Cancer Specialists, Bluffton and Hilton Head, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Kier","sequence":"additional","affiliation":[{"name":"Cancer Research Consortium of West Michigan, Traverse City, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen J.","family":"Calfa","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-890X","authenticated-orcid":true,"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8010","authenticated-orcid":true,"given":"Jared D.","family":"Acoba","sequence":"additional","affiliation":[{"name":"The Queen's Medical Center, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00869-z"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00222-7"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.4.7657"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3620"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5118"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01558-1"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500017"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_3_11_13_2","article-title":"Phase II study of erdafitinib in patients with tumors with FGFR amplifications: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K1","author":"Gong J","unstructured":"Gong J, Mita AC, Wei Z, et al: Phase II study of erdafitinib in patients with tumors with FGFR amplifications: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K1. JCO Precis Oncol 10.1200\/PO.23.00406","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_14_2","article-title":"Phase II study of erdafitinib in patients with tumors with fibroblast growth factor receptor mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K2","author":"Gong J","unstructured":"Gong J, Mita AC, Wei Z, et al: Phase II study of erdafitinib in patients with tumors with fibroblast growth factor receptor mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K2. JCO Precis Oncol 10.1200\/PO.23.00407","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_15_2","article-title":"Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: A pooled analysis of early-phase clinical trials","author":"Grochot R","unstructured":"Grochot R, Joshi K, Cammarota A, et al: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: A pooled analysis of early-phase clinical trials. JCO Precis Oncol 10.1200\/PO-24-00896","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103625"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.001"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw435.22"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69446-4"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611406"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_3_11_23_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.11.002"},{"key":"e_1_3_11_25_2","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_26_2","article-title":"Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Worden FP","unstructured":"Worden FP, Pisick E, Rothe M, et al: Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO-24-00477","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_27_2","article-title":"Olaparib in patients with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Carrizosa DR","unstructured":"Carrizosa DR, Rothe M, Mangat PK, et al: Olaparib in patients with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO-25-00716","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_28_2","article-title":"Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Rothe M, Mangat PK, et al: Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO-25-00649","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_29_2","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Ganti AK","unstructured":"Ganti AK, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.23.00041","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_30_2","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00609","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_31_2","article-title":"Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the Targeted Agent and Profiling Utilization Registry Study","author":"Schuetze S","unstructured":"Schuetze S, Rothe M, Mangat PK, et al: Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol 10.1200\/PO.24.00219","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104545"},{"key":"e_1_3_11_33_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_11_35_2","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Sahai V","unstructured":"Sahai V, Rothe M, Mangat PK, et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00527","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_36_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_37_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_38_2","article-title":"Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Meric-Bernstam F","unstructured":"Meric-Bernstam F, Rothe M, Mangat PK, et al: Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.23.00385","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_39_2","article-title":"Palbociclib in patients with Non\u2013small-cell lung cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with Non\u2013small-cell lung cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_40_2","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study","author":"Al Baghdadi T","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E, et al: Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.19.00124","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00702"},{"key":"e_1_3_11_42_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_43_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_44_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_11_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_11_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_11_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_11_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5009"},{"key":"e_1_3_11_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"e_1_3_11_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.018"},{"key":"e_1_3_11_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00275-9"},{"key":"e_1_3_11_53_2","first-page":"1961","article-title":"Erdafitinib or erdafitinib plus cetrelimab for patients with metastatic urothelial carcinoma and FGFR alterations: Final results from the phase II NORSE study","volume":"389","author":"Loriot Y","year":"2023","unstructured":"Loriot Y, Powles T, Moreno V, et al: Erdafitinib or erdafitinib plus cetrelimab for patients with metastatic urothelial carcinoma and FGFR alterations: Final results from the phase II NORSE study. J Clin Oncol 389:1961-1971, 2023","journal-title":"J Clin Oncol"},{"key":"e_1_3_11_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0697"},{"key":"e_1_3_11_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.8"},{"key":"e_1_3_11_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01157-0"},{"key":"e_1_3_11_57_2","article-title":"OncoKB: A precision oncology knowledge base","author":"Chakravarty D","unstructured":"Chakravarty D, Gao J, Phillips S, et al: OncoKB: A precision oncology knowledge base. JCO Precis Oncol 10.1200\/PO.17.00011","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0467"},{"key":"e_1_3_11_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05066-5"},{"key":"e_1_3_11_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3746"},{"key":"e_1_3_11_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1665"},{"key":"e_1_3_11_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8622"},{"key":"e_1_3_11_63_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2944"},{"key":"e_1_3_11_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.09.001"},{"key":"e_1_3_11_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3803"},{"key":"e_1_3_11_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx107"},{"key":"e_1_3_11_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02630"},{"key":"e_1_3_11_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30666-0"},{"key":"e_1_3_11_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0478"},{"key":"e_1_3_11_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.041"},{"key":"e_1_3_11_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604456"},{"key":"e_1_3_11_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5375"},{"key":"e_1_3_11_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou148"},{"key":"e_1_3_11_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.196"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:59:28Z","timestamp":1791403168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1200\/PO-26-00454"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00454","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600454"}}